多發性硬化症藥物市場的增長，趨勢和預測（2020-2025）

Multiple Sclerosis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: 2022年01月17日 | 出版商:

Mordor Intelligence Pvt Ltd | 英文 112 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全貌
簡介
目錄

簡介

由於多發性硬化症的患病率增加以及公司對多發性硬化症產品的關注度越來越高，未來多發性硬化症藥物的市場規模將高速增長。預計會擴大。

大型製藥公司正在藥物開發過程中進行大量投資，併計劃針對盡可能多的適應症，以服務大量客戶。這也有利於多發性硬化症市場。例如，正在開發的用於多發性硬化症的藥物包括復發緩解型多發性硬化症，繼發性晚期多發性硬化症，原發性晚期多發性硬化症和髓磷脂修復或神經保護作用。有藥品。

市場領先者Biogen正在開發富馬酸地洛西美酯，目前處於開發的第三階段。同樣，諾華正在開發Ofatumumab，該藥物也處於第3期。

與上述公司類似，輝瑞公司等其他公司也在開髮用於多發性硬化症的藥物。這表明在預測期內，用於多發性硬化症的管線藥物可能會促進市場的增長。

該報告調查了多種硬化症藥物的市場，提供了市場概況，按藥物類型，給藥途徑，地區和進入市場的公司概況的趨勢。

Key Highlights

Big pharmaceutical companies have been investing heavily in the drug development process and are planning to target as many indications as possible, in order to cater to a large number of customers. Owing to this, the MS market has also been benefiting. For instance, the drugs being developed for multiple sclerosis include the drugs for Relapsing-remitting MS, Secondary progressive MS, Primary progressive MS, and Myelin repair or neuroprotection.
Biogen, a leading player in the market studied has been developing Diroximel fumarate, which is currently in phase III of development; similarly, Novartis has been developing Ofatumumab, which is also in Phase III.
Similar to the above-mentioned companies, there have been other pharmaceutical players, such as Pfizer Inc., which have been developing drugs for MS. This indicates that pipeline drugs for MS may boost the studied market's growth in the forecast period.

Key Market Trends

The Oral Route of Administration is Expected to Witness Rapid Growth in Future

Classical multiple sclerosis (MS) treatments using first-line injectable drugs, even though they have been widely applied, remain to be a foremost concern in terms of therapeutic adherence and efficacy. Novel oral drugs, recently approved for the treatment of MS, represent significant advances in the therapy. The oral route of administration evidently supports patient satisfaction and increases therapeutic compliance.

If someone is not comfortable with needles, there are oral options for treating MS. Taken daily or twice daily, oral medications require one to maintain a regular dosing schedule. These are the easiest to be self-administered.

The currently available oral multiple sclerosis drugs include Aubagio (teriflunomide), Gilenya (fingolimod), and Tecfidera (dimethyl fumarate).

In March 2019, the US Food and Drug Administration approved Mayzent (siponimod) tablets to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

North America to Dominate the Market

The market for multiple sclerosis therapeutics is expected to show high growth in the North America region, which is majorly attributed to the presence of key players and the rising prevalence of the disease in this region. The United States is the major market for companies, such as Biogen, Novartis AG, and Sanofi SA, among others. Therefore, these companies have been focusing more on establishing their new drugs in this market studied, which ultimately has been contributing to the growth of this region.

Furthermore, as per the National Multiple Sclerosis Society, Canada is a country with the highest prevalence of MS in the world (291 per 100,000). In the case of the United States, the National MS Society estimated that there are around 1 million people in the country living with MS.

Hence, due to the high prevalence and presence of the key players, North America is expected to dominate the market studied.

Competitive Landscape

The market for MS therapeutics is consolidated, as there are few players in this market. These companies are the big pharmaceutical companies that have been focusing on pipeline drugs for multiple sclerosis. With the rising R&D investment in the pharmaceutical industry, it is believed that more companies may enter the market studied in the future, and the competition may increase.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
- 4.2.1 Raised Cases of Multiple Sclerosis across the World
- 4.2.2 Growing Focus of Companies on Pipeline Products for MS
4.3 Market Restraints
- 4.3.1 Side Effects Associated with the Medication
- 4.3.2 High Cost of the Drugs
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Drug Type
- 5.1.1 Large-molecule Drugs
- 5.1.2 Small-molecule Drugs
5.2 By Route of Administration
- 5.2.1 Oral
- 5.2.2 Injectable and Others
5.3 Geography
- 5.3.1 North America
  - 5.3.1.1 United States
  - 5.3.1.2 Canada
  - 5.3.1.3 Mexico
- 5.3.2 Europe
  - 5.3.2.1 Germany
  - 5.3.2.2 United Kingdom
  - 5.3.2.3 France
  - 5.3.2.4 Italy
  - 5.3.2.5 Spain
  - 5.3.2.6 Rest of Europe
- 5.3.3 Asia Pacific
  - 5.3.3.1 China
  - 5.3.3.2 Japan
  - 5.3.3.3 India
  - 5.3.3.4 Australia
  - 5.3.3.5 South Korea
  - 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East & Africa
  - 5.3.4.1 GCC
  - 5.3.4.2 South Africa
  - 5.3.4.3 Rest of Middle East & Africa
- 5.3.5 South America
  - 5.3.5.1 Brazil
  - 5.3.5.2 Argentina
  - 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
- 6.1.1 Teva Pharmaceuticals
- 6.1.2 Novartis AG
- 6.1.3 Pfizer Inc.
- 6.1.4 Biogen Idec
- 6.1.5 Bayer AG
- 6.1.6 Sanofi SA
- 6.1.7 Mylan NV
- 6.1.8 Merck KGaA (Serono)
- 6.1.9 F. Hoffmann-La Roche AG
- 6.1.10 Acorda Therapeutics Inc.